FANNIN was established in 1829 and today is part of the DCC group. The company’s MicroClave needle-free IV access system is proven for use on central and peripheral venous access.
It is validated for 600 activations over a seven day period with published independent clinical evidence illustrating reduced infection risk. The company also provides Gama Alcoholic 2% Chlorhexidine wipes, Pall IV filters, surgically implantable ports with safety needles, plus ported or non-ported safety cannulae that will reduce the risk of needle stick injury. These all form a part of its total IV therapy portfolio.
